Absence Of R1881 Research Articles

Abstract 4397: Gli Activation by Steroid Receptors in Prostate and Breast Cancer Cells

Abstract Background: The nuclear steroid receptor superfamily encompasses a group of proteins best known for their functions as primary transcription factors that are conditionally active when bound to a ligand. Here, we show that prominent members of this family (androgen receptor [AR], estrogen receptor [ER-α] and glucocorticoid receptor [GR]) have a secondary function of coordinately activating the Gli family of transcription factors. Previously, we found that liganded AR recognizes and binds to Gli2/Gli3 proteins at their Protein Processing Domains. This binding prevents their degradation and stabilizes them in their high molecular weight, transcriptionally-active forms. This interaction bypasses the need for signaling through Hedgehog/Smoothened to stabilize Gli. To determine whether other steroid receptors have this activity, we tested the ability of human ER-α and GR to bind to Gli3 and whether they increased Gli activity in exogenous (293FT) and endogenous breast and prostate cancer cell systems. Methods: Human AR, ER-α or GR expression vectors were co-transfected into 293FT cells along with a myc-tagged Gli3. Protein extracts were tested for co-immunoprecipitation of AR-/ER-/GR-Gli3 complexes. 293FT cells were co-transfected with AR, ER, or GR along with a Gli-reporter vector. Luciferase activity was measured in transfected cells upon treatment with vehicle, R1881 (AR ligand), estradiol (E2-ER ligand); or dexamethasone (dex-GR ligand). LNCaP (express AR), MCF7 (express ER) or LNCaP-AI cells (express GR) were transfected with reporter in the presence or absence of R1881, E2, dex or vehicle and luciferase activity was measured. AR-/ER-Gli3 complexes were detected by in situ proximity ligation assays in prostate cancer or breast cancer cells. The effect of AR or ER-α siRNA knockdown in LNCaP or MCF7 cells on Gli3 protein stability was measured on western blot. Results: Pulldowns of AR, ER or GR co-immunoprecipitates with Gli3. Transfection with AR or ER increased Gli reporter activity in the presence of vehicle but was further increased by R1881 or E2 treatment. Gli reporter activity was unchanged by transfection with GR in the presence of vehicle but the presence of 5 or 10nM of dex tripled this activity. Gli-luciferase activity was significantly increased in R1881-treated LNCaP cells, E2-treated MCF7 cells and in dex-treated LNCaP-AI cells. PLA detected the presence of AR-Gli3 and ER-Gli3 complexes in nuclei of LNCaP and MCF7 cells. AR and ER-α knockdown destabilized Gli3 protein in LNCaP and MCF7 cells. Conclusion: Collectively our results established a secondary function (Gli activation) shared by an important evolutionary spectrum of human steroid receptors (AR, ER, and GR). As Gli is oncogenic and regulates the expression of many growth-related genes, our observations may explain the pro-oncogenic effects of steroid receptors in steroid-dependent tumour systems. Citation Format: Shabnam Massah, Na Li, Sarah Truong, Jane Foo, Gail Prins, Ralph Buttyan. Gli Activation by Steroid Receptors in Prostate and Breast Cancer Cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4397.

SUN-001 Analysis of Isoform Specific Differential Splicing Effects in Prostate Cancer

The androgen receptor (AR) is a hormone activated transcription factor which is important for the growth and progression of prostate cancer (PCa). Metastatic PCa is treated with androgen deprivation therapy (ADT) based regimen but eventually, these tumours develop resistance through multiple mechanisms that reactivate AR. These include expression of constitutively active AR splice variants that lack a ligand binding domain such as AR-V7. To characterize the common and unique activities of AR and AR-V7, we engineered LNCaP and VCaP cell lines that express AR-V7 in response to doxycycline and performed RNA-Seq. Many genes were found to be regulated by both AR and AR-V7, but there were also genes regulated by only one isoform. Moreover, both isoforms altered mRNA splicing of numerous target genes, in some cases without altering overall levels of mRNA. In many cases, the alterations in splicing are AR isoform specific. To understand the differential splicing by AR isoforms, CD44 mini-gene splicing assay and studies of endogenous target genes are being done. The CD44 mini-gene contains an MMTV promoter and is a multi-functional molecule containing two variable exons, v4 and v5 that can be either included or excluded during the splicing process. Both AR and AR-V7 induce transcription from an MMTV promoter. Co-transfection of AR or AR-V7 with the CD44 mini-gene in Hela cells demonstrated that CD44 splicing was altered by AR and its variant AR-V7. R1881 treated samples showed a shift to RNA products resulting from the skipping of both variable exons. Treatment with R1881 showed a decrease in the PSI (Percent Spliced Inclusion) as compared to obtained in the absence of R1881 or AR-V7. In contrast, AR-V7 minimally induced single exon skipping as compared to vehicle. These observations suggest that AR and its variants can have marked effects on RNA splicing to produce radically different proteins with different splicing/inclusion ratio. Analysis of the RNA-Seq data revealed that multiple types of splicing events are affected by the AR isoforms. For instance, whether an isoform favours exclusion or inclusion of a particular exon is event specific. A comparison of splicing in VCaP and LNCaP models showed that only a subset of events were common to the two models. One of the most differentially regulated events in both lines is an exon inclusion/exclusion event in PGAP2. Both isoforms increase the inclusion/exclusion ratio. However, further analysis showed that AR-V7 preferentially increased the levels of inclusion, but did not affect the basal levels of skipping. Also, AR increased the inclusion/skipping ratio through repression of expression of the skipped product. Similar analyses for other splicing events are ongoing. Our studies will provide a better understanding for the molecular basis for isoform specific actions and the role of AR/AR-V7 in the regulation of mRNA transcription and splicing.

Abstract 5455: Differential regulation of E2A (TCF3) by androgens in prostate cancer cells.

Abstract Introduction: E2A (TCF3) is a multifunctional basic helix loop helix (bHLH) transcription factor. E2A promotes cell differentiation, acts as a negative regulator of cell proliferation in normal cells and cancer cell lines and is required for normal B-cell development. Previous studies from our laboratory has shown that E2A expression is highly increased in prostate cancer as compared to normal prostate and that it acts as a tumor promoter in prostate cancer. Given the diverse biological pathways regulated/ influenced by E2A little is known about its regulation in prostate cancer. Experimental design: E2A expression in androgen sensitive LNCaP and insensitive C81 prostate cancer cell lines was determined by western blot after treatments with androgen receptor (AR) agonist R1881 and antagonist casodex. Putative Androgen Response Elements (ARE) were identified in the first intronic region of the E2A gene using some of the online bioinformatics tools and confirmed by Chromatin Immunoprecipitation (ChIP) with AR antibody and Luciferase reporter assays on the above mentioned cell lines after treatments with R1881 and casodex. Results: E2A expression was found to increase with the increasing aggrasiveness of prostate cancer cell lines as compared to normal prostate epithelial cell line RWPE1. When androgen responsive cell line LNCaP was treated with R1881 there was an increased expression of E2A which decreased upon treatment with antiandrogen casodex whereas the E2A expression remained unaltered upon similar treatments in androgen insensitive cell line C81. The first intronic region of the E2A gene was predicted to contain two putative ARE sites. ChIP after treatment of LNCaP and C81 cells with R1881 and casodex showed that the intronic region was bound by AR in LNCaP cells only in the presence of R1881, whereas C81 cells showed a pulldown with AR in presence as well as absence of R1881. Similar results were observed in luciferase reporter assays indicating that E2A is transactivated by AR in LNCaP cell lines whereas it is independent of androgens in C81 cell line. Furthermore, Luciferase reporter assays also confirmed that only one of the two predicted putative AREs was functionally active and responsible for the androgen mediated regulation of E2A. Conclusion: Our results indicate that E2A is differentially regulated in Prostate cancer cell lines. The increased expression of E2A and its role as a tumor promoter in prostate cancer cell lines may be contributed to its loss of androgen dependence as is evident in its progression from androgen dependent LNCaP to independent C81 cells. Acknowledgements: This study was supported by NIH/NCI RO1 CA128914 and NIH/NCRR/RCMI G12RR03062. Citation Format: Divya Patel, Jaideep Chaudhary. Differential regulation of E2A (TCF3) by androgens in prostate cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5455. doi:10.1158/1538-7445.AM2013-5455

Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells

TOK-001 and abiraterone are potent 17-heteroarylsteroid (17-HAS) inhibitors of Cyp17, one of the rate-limiting enzymes in the biosynthesis of testosterone from cholesterol in prostate cancer cells. Nevertheless, the molecular mechanism underlying the prevention of prostate cell growth by 17-HASs still remains elusive. Here, we assess the effects of 17-HASs on androgen receptor (AR) activity in LNCaP and LAPC-4 cells. We demonstrate that both TOK-001 and abiraterone reduced AR protein and mRNA expression, and antagonized AR-dependent promoter activation induced by androgen. TOK-001, but not abiraterone, is an effective apparent competitor of the radioligand [(3)H]R1881 for binding to the wild type and various mutant AR (W741C, W741L) proteins. In agreement with these data, TOK-001 is a consistently superior inhibitor than abiraterone of R1881-induced transcriptional activity of both wild type and mutant AR. However, neither agent was able to trans-activate the AR in the absence of R1881. Our data demonstrate that phospho-4EBP1 levels are significantly reduced by TOK-001 and to a lesser extent by abiraterone alcohol, and suggest a mechanism by which cap-dependent translation is suppressed by blocking assembly of the eIF4F and eIF4G complex to the mRNA 5' cap. Thus, the effects of these 17-HASs on AR signaling are complex, ranging from a decrease in testosterone production through the inhibition of Cyp17 as previously described, to directly reducing both AR protein expression and R1881-induced AR trans-activation.

Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.

Prostate specific membrane antigen (PSMA) is overexpressed in prostatic adenocarcinoma (CaP), and its expression is negatively regulated by androgen stimulation. However, it is still unclear which factors are involved in this downregulation. TMPRSS2-ERG fusion is the most common known gene rearrangement in prostate carcinoma. Androgen stimulation can increase expression of the TMPRSS2-ERG fusion in fusion positive prostate cancer cells. The purpose of this investigation is to determine whether PSMA expression can be regulated by the TMPRSS2-ERG gene fusion. We employed two PSMA positive cell lines: VCaP cells, which harbor TMPRSS2-ERG fusion, and LNCaP cells, which lack the fusion. After 24 hours of androgen treatment, TMPRSS2-ERG mRNA level was increased in VCaP cells. PSMA mRNA level was dramatically decreased in VCaP cells, while it only has moderate change in LNCaP cells. Treatment with the androgen antagonist flutamide partially restored PSMA expression in androgen-treated VCaP cells. Knocking down ERG by siRNA in VCaP cells enhances PSMA expression both in the presence and absence of synthetic androgen R1881. Overexpressing TMPRSS2-ERG fusions in LNCaP cells downregulated PSMA both in the presence or absence of R1881, while overexpressing wild type ERG did not. Using PSMA-based luciferase reporter assays, we found TMPRSS2-ERG fusion can inhibit PSMA activity at the transcriptional level. Our data indicated that downregulation of PSMA in androgen-treated VCaP cells appears partially mediated by TMPRSS2-ERG gene fusion.

Abstract 4057: Negative regulation of prostate specific membrane antigen by androgen is mediated by TMPRSS2-ERG gene fusion in VCaP prostate cancer cells

Abstract Prostate specific membrane antigen (PSMA) is a type II transmembrane glycoprotein over-expressed in prostate carcinoma. Elevated PSMA expression has been correlated with aggressive disease and risk of early recurrence after radical prostatectomy. This molecule is also expressed in the neovasculature of multiple nonprostate solid tumors. Consequently, this unique cell marker has been targeted for diagnosis and therapy of prostate cancer (PCa) and other malignancies. Recently studies have shown that a significant fraction of PCa harbor a signature gene fusion between the androgen-responsive TMPRSS2 gene and transcription factors in the ETS family - most commonly ERG. The TMPRSS2-ERG fusion is likely the cause for over-expression of ERG in PCa. PSMA, unlike ERG, is negatively regulated by androgen. Elucidation of the relationship between TMPRSS2 gene fusions and PSMA expression could reveal mechanisms to alter PSMA expression and disease course. The purpose of this investigation was to determine whether PSMA gene expression could be regulated by the TMPRSS2-ERG fusion in prostate cancer cells. We employed VCaP cells, which harbor TMPRSS2-ERG fusion, and LNCaP cells, which lack the fusion. Our data showed that after 24h androgen R1881 treatment, ERG and TMPRSS2-ERG mRNA level were increased in VCaP cells and unchanged in LNCaP cells. PSMA and androgen receptor (AR) mRNA level were dramatically decreased in VCaP cells and only modestly decreased in LNCaP cells. Treatment with the androgen antagonist flutamide partially restored PSMA and AR expression in androgen-treated VCaP cells. Knocking down ERG by siRNA in VCaP cells enhances PSMA expression both in the presence and absence of R1881. When LNCaP cells transfected with TMPRSS2-ERG fusion transcripts, PSMA was down-regulated both in the presence or absence of R1881. Using PSMA-based luciferase reporter assays, we found TMPRSS2-ERG fusion can inhibit PSMA activity at the transcriptional level. Our data indicated that negative regulation of PSMA by androgen is mediated by TMPRSS2-ERG gene fusion in VCaP prostate cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4057.

230 INHIBITION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN GENE-EXPRESSION IS MEDIATED BY TMPRSS2:ERG GENE FUSION IN VCAP PROSTATE CANCER CELLS

You have accessJournal of UrologyProstate Cancer: Basic Research II1 Apr 2010230 INHIBITION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN GENE-EXPRESSION IS MEDIATED BY TMPRSS2:ERG GENE FUSION IN VCAP PROSTATE CANCER CELLS Pravin Rao, Lihong Yin, and Warren Heston Pravin RaoPravin Rao Lakewood, OH More articles by this author , Lihong YinLihong Yin Cleveland, OH More articles by this author , and Warren HestonWarren Heston Cleveland, OH More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.288AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is over-expressed in prostatic adenocarcinoma (CaP). Levels of PSMA expression have been correlated with aggressive disease and risk of early recurrence after radical prostatectomy (RP). Studies have shown that a significant fraction of CaP's harbor a signature gene fusion between the androgen-responsive TMPRSS2 gene and transcription factors in the ETS family – most commonly ERG. The TMPRSS2-ERG fusion is likely the cause for over-expression of ERG in CaP. PSMA, unlike ERG, is negatively regulated by androgen. Elucidation of the relationship between TMPRSS2 gene fusions and PSMA expression could reveal mechanisms to alter PSMA expression and disease course. The purpose of this investigation was to determine whether PSMA gene expression could be regulated by the TMPRSS2-ERG fusion in prostate cancer cells. METHODS VCaP cells (which harbor the TMPRSS2:ERG fusion) and LNCaP cells (which do not) were incubated with vehicle or the androgen-receptor antagonist flutamide prior to treatment with synthetic androgen R1881. In addition, transfection of siRNA against human ERG was performed to create ERG knockdown in VCaP cells. Reverse transcription (RT) PCR as well as real-time RT PCR were used to detect and quantify transcription of ERG, TMPRSS2:ERG, PSMA, and androgen receptor (AR) genes. Using the comparative threshold cycles method, the quantification of these transcripts was performed, and expression was compared in various androgen-treated and untreated VCaP and LNCaP cells. RESULTS After 24-hour androgen treatment, ERG and TMPRSS2-ERG mRNA level were increased in VCaP cells and unchanged in LNCaP cells. PSMA and androgen receptor (AR) mRNA level were dramatically decreased in VCaP cells and modestly decreased in LNCaP cells. Treatment with the androgen antagonist flutamide partially restored PSMA and AR expression in androgen-treated VCaP cells. Knocking down ERG by siRNA in VCaP cells enhances PSMA mRNA expression both in the presence and absence of R1881, while it has minimal change of AR mRNA in VCaP-ERG knock down cells. CONCLUSIONS Down-regulation of PSMA in androgen-treated VCaP cells appears partially mediated by the TMPRSS2:ERG gene fusion. Since PSMA has been associated with aggressive disease and early biochemical failure after RP, further elucidation of the relationship between TMPRSS2 gene fusions and PSMA could reveal potential novel targets for treatment of prostate cancer. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e90 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Pravin Rao Lakewood, OH More articles by this author Lihong Yin Cleveland, OH More articles by this author Warren Heston Cleveland, OH More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...

Induction of the SUMO-specific Protease 1 Transcription by the Androgen Receptor in Prostate Cancer Cells

Prostate cancer, the most frequently diagnosed carcinoma in males, is readily modulated via the transcriptional activity of androgen receptors. Our recent publication reported that androgen receptor-dependent transcription is significantly elevated with expression of the human sentrin/SUMO-specific protease (SENP1) in the androgen-sensitive human prostate cancer cell line (LNCaP). In situ hybridization studies indicated an elevation of SENP1 message in prostatic intraepithelial neoplasia and prostate cancer lesions as compared with normal prostate epithelia. This study aimed to delineate the mechanism for the regulation of SENP1 message and to determine the pathophysiological consequence of SENP1 induction with respect to prostate cancer. Real-time PCR confirmed the elevation of SENP1 mRNA in prostate cancer cells as compared with normal prostate epithelial cells. Chronic androgen exposure of LNCaP cells prompted an enhancement in the SENP1 transcript selectively. This androgen-mediated augmentation of SENP1 was absent with co-administration of the androgen receptor antagonist bicalutamide and in androgen receptor-negative prostate cancer PC-3 cells, indicating an androgen receptor-dependent event. Activation of the androgen receptor was required for binding an identified androgen response element and positively regulating SENP1 promoter activity. Abrogation of elevated SENP1 mRNA in prostate cancer cells significantly decreased androgen-mediated cell growth. Because increased SENP1 expression directly modulated androgen receptor-dependent cell proliferation and transcription, SENP1 could play an important role in prostate carcinogenesis.

Cell-specific Regulation of Androgen Receptor Phosphorylation in Vivo

The biological ramifications of phosphorylation of the androgen receptor (AR) are largely unknown. To examine the phosphorylation of AR at serine 213, a putative substrate for Akt, a phosphorylation site-specific antibody was generated. The use of this antibody indicated that AR Ser-213 is phosphorylated in vivo and that phosphorylation is tightly regulated in a cell type-specific manner. Furthermore, Ser-213 phosphorylation took place with rapid kinetics and was inhibited by the phosphatidylinositol 3-kinase inhibitor LY294002. Phosphorylation occurred in response to R1881 and dihydrotestosterone but weakly if at all in response to testosterone. It did not occur in response to AR antagonists or growth factor stimulation in the absence of an AR agonist. Transcription assays using an AR-responsive reporter gene construct showed that activated phosphatidylinositol 3-kinase inhibited transcription mediated by wild type AR but not that of a mutant AR variant (S213A), which could not be phosphorylated at Ser-213. By immunohistochemistry, the AR Ser(P)-213 antigen was detected in prostate epithelial but not stromal cells despite the fact that an antibody recognizing both phosphorylated and non-phosphorylated forms of AR demonstrates that AR is present in both cell types as expected. In fetal tissue the AR-Ser(P)-213 antigen was present in epithelial cells of the urogenital sinus when endogenous androgen levels were high and activated Akt was prevalent, but absent at a later stage of development when endogenous androgen levels were low and Akt activation was minimal. Immunoreactivity was evident in differentiated cells lining the lumen of the urogenital sinus but not in rapidly dividing, Ki67 positive cells within the developing prostate or stromal tissue, suggesting that site-specific phosphorylation of AR Ser-213 by cellular kinases occurs in a non-proliferating cellular milieu.

289. Highly Inducible and Prostate Specific Oncolytic Adenovirus with E1A-AR Chimera

Top of pageAbstract Previously, we demonstrated prostate-specific replication and passive cell lysis using E1A driven by a prostate-specific antigen promoter (PSA) and enhancer (PSE). However, the expression of E1A relies on promoters that utilize the androgen receptor (AR) for optimal function. Recently we have discovered that E1A and AR are mutually antagonistic in their transcriptional regulation. We demonstrate that a chimeric fusion of AR with the E1A converts an androgen receptor repressor to a co-activator. Here, we describe the features of conditionally replication-competent adenoviruses (CRADs) with E1A-AR chimeric expression in prostate cancer cells and non-prostate cancer cells. We constructed a series of recombinant chimeric E1A-AR viruses including wild type AR (E1A-ARwt), transactivation domain (E1A-TAD), and a full-length AR with a point mutation in the ligand binding domain (E1A-ARC685Y), under the control of the prostate-specific enhancer (PSE) and rat probasin promoter (PBN). The E1A function of these viruses was evaluated in prostate cancer cells and non-prostate cancer cells using an adenovirus with Fiber-IRES-GFP lacking E1A as a reporter. The wild type Ad5 with an E3-deletion replicates in both prostate cancer cells and non-prostate cancer cells. Replication of this virus is decreased by 50% by activated androgen receptors in the LNCaP cell line. The CRAD Ad5PSE-PBN-E1A displayed a rapidly inducible replication in prostate cancer cells in the presence of R1881, however, it had a delayed and relatively high expression in the absence of R1881. The chimeric CRADs Ad5PSE-PBN-E1A-AR and Ad5PSE-PBN-E1A-C685Y displayed marked induction of E1A in LNCaP (AR+), no induction in PC3 (AR-), and non-prostate cancer cells Hela in the presence of hormone, and no expression in any cell line in the absence of hormone. The cytopathic effect (CPE) of these chimeric viruses was also confirmed using crystal violet staining. Our highly engineered E1A-AR chimeras not only convert a negative regulatory process into a positive regulatory process, but also greatly enhance the tissue specificity and the regulation of viral replication in the prostate. This strategy dramatically reduces toxicity in non-prostate tissue, while maintaining prostate specificity.

An Androgen Response Element in a Far Upstream Enhancer Region Is Essential for High, Androgen-Regulated Activity of the Prostate-Specific Antigen Promoter

Prostate-specific antigen (PSA) is expressed at a high level in the luminal epithelial cells of the prostate and is absent or expressed at very low levels in other tissues. PSA expression can be regulated by androgens. Previously, two functional androgen-response elements were identified in the proximal promoter of the PSA gene. To detect additional, more distal control elements, DNaseI-hypersensitive sites (DHSs) upstream of the PSA gene were mapped in chromatin from the prostate-derived cell line LNCaP grown in the presence and absence of the synthetic androgen R1881. In a region 4.8 to 3.8 kb upstream of the transcription start site of the PSA gene, a cluster of three DHSs was detected. The middle DNAseI-hypersensitive site (DHSII, at ∼−4.2 kb) showed strong androgen responsiveness in LNCaP cells and was absent in chromatin from HeLa cells. Further analysis of the region encompassing DHSII provided evidence for the presence of a complex, androgen-responsive and cell-specific enhancer. In transient transfected LNCaP cells, PSA promoter constructs containing this upstream enhancer region showed approximately 3000-fold higher activity in the presence than in the absence of R1881. The core region of the enhancer could be mapped within a 440-bp fragment. The enhancer showed synergistic cooperation with the proximal PSA promoter and was found to be composed of at least three separate regulatory regions. In the center, a functionally active, high-affinity androgen receptor binding site (GGAACATATTGTATC) could be identified. Mutation of this element almost completely abolished PSA promoter activity. Transfection experiments in prostate and nonprostate cell lines showed largely LNCaP cell specificity of the upstream enhancer region, although some activity was found in the T47D mammary tumor cell line.